荆志成，1971年生，籍贯山东。北京协和医院心内科主任，北京协和医学院首批长聘教授；国家自然科学基金委杰青，教育部国家级重大人才项目，科技部国家级重大人才项目入选者；中国农工党中央委员，中国农工党北京市委员会副主委，中国农工党第十六届中央医疗卫生工作委员会副主任，北京市政协委员，北京市人民政协理论与实践研究会第五届理事会成员。被欧洲心脏杂志赞誉为“中国肺血管医学先锋”。

主要从事心血管疾病的医、教、研等工作，特别是针对先天性心脏病、肺栓塞和肺动脉高压等疑难危重、罕见疾病的临床、人群、基础和转化研究，包括新药和新医疗器械开发，规范和标准制定，收集保护我国患者遗传资源，建设全链条、全维度生物样本银行，国际学术交流，以及中青年人才培养的工作。

天美麻花星空

1. Zhou YP#, Wei YP#, Yang YJ, Xu XQ, Wu T, Liu C, Mei KY, Peng FH, Wang HP, Sun K, Li JY, Wang HF, Li MT, Wang DL, Miao Q, Jiang X*, Jing ZC*. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. J Am Coll Cardiol. 2022 Apr 19;79(15):1477-1488. (IF = 27.203)

2. Jiang X#, Zhou YJ#,Zhou YP#, Peng FH, Wang L, Ma W, Cao YS, Pan X, Zhang GC, Zhang F, Fan FL, Wu BX, Huang W, Yang ZW, Hong C, Li MT, Wang YN, Xu XQ, Wang DL, Zhang SY, Jing ZC*. Clinical features and survival in Taksyasu's arteritis-associated pulmonary hypertension: a nationwide study. Eur Heart J. 2021 Sep 10. (IF = 29.983)

3. Yan Y#, He YY#, Jiang X#, Wang Y, Chen JW, Zhao JH, Ye J, Lian TY, Zhang X, Zhang RJ, Lu D, Guo SS, Xu XQ, Sun K, Li SQ, Zhang LF, Zhang X, Zhang SY, Jing ZC*. DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension. Sci Adv. 2020 Dec 9;6(50). (IF = 14.136)

4. He YY#, Yan Y#, Jiang X, Zhao JH, Wang Z, Wu T, Wang Y, Guo SS, Ye J, Lian TY, Xu XQ, Zhang JL, Sun K, Peng FH, Zhou YP, Mao YM, Zhang X, Chen JW, Zhang SY, Jing ZC*, Spermine promotes pulmonary vascular remodeling and its synthase is a therapeutic target for pulmonary arterial hypertension. Eur Respir J. 2020 Nov 5;56(5):2000522.  doi: 10.1183/13993003.00522-2020. (IF = 16.671)

5. Wang XJ#, Xu XQ#, Sun K#, Liu KQ, Li SQ, Jiang X, Zhao QH, Wang L, Peng FH, Ye J, Wu Y, Jiang R, Zhang J, Huang W, Bei WB, Yan Y, Li JH, Liu QQ, Li S, Wang Y, Zhang SY, Zhang X, Jing ZC*. Association of rare PTGIS variants with susceptibility and pulmonary vascular response in patients with idiopathic pulmonary arterial hypertension. JAMA Cardiol. 2020 Apr 1; 5(6): 677-684. (IF=14.676, R)

6. Wang XJ#, Lian TY#, Jiang X, Liu SF, Li SQ, Jiang R, Wu WH, Ye J, Cheng CY, Du Y, Xu XQ, Wu Y, Peng FH, Sun K, Mao YM, Yu H, Liang C, John YJ, Zhang SY, Zhang X, Jing ZC*. Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension. Eur Respir J. 2019 Mar 14;53(3):1801609. doi: 10.1183/13993003.01609-2018. (IF=12.399, R)

7. Jing ZC#*, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Arneson C, Laliberte K, and Rubin LJ. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized controlled trial. Circulation.2013 Feb 5;127(5):624-633. (IF=14.948, C100, F1000, PIII)

8. Jing ZC#*, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè Nfor the Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study. Vadenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study.Am J Respir Crit Care Med. 2011, 183(12):1723-1729. (IF=11.080, R, PIII)

9. Jing ZC#*, Jing X#, Han ZY#, Xu XQ, Wang Y, Wu Y, Lv H, Ma CR, Yang YJ, Pu JL. Iloprost for Pulmonary Vasodilator Testing in Idiopathic Pulmonary Arterial Hypertension. Eur Respir J. 2009 Jun;33:1354-1360. (IF=5.527, R)

10. Jing ZC#, Xu XQ#, Han ZY#, Wu Y, Deng KW, Wang H, Wang ZW, Cheng XS, Xu B, Hu SS,Hui RT, Yang YJ. Registry and survival study of Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007 Aug;132:373-379. (IF=4.143, C100,F1000)